Relmada Therapeutics RLMD
NASDAQ RLMD
$3.31 +0.10 (+2.95%)
As of: Oct 22, 2026 · 3:37 PM EDT

Relmada Therapeutics (RLMD) FCF Margin (2012 - 2023)

Updated

Relmada Therapeutics' FCF Margin came in at -196.12% for FY2013, down 100.86 percentage points from -95.27% in FY2012.

Analysis

Relmada Therapeutics (RLMD) FCF Margin (2012 - 2023) Analysis & Trends

  • Per Business Quant, earlier years put FCF Margin at -95.27% in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Eli Lilly 1,170.46 Bn 1,139.04 Bn 19.71 Bn 33.76%
2 Johnson & Johnson 648.38 Bn 568.24 Bn 17.30 Bn 25.03%
3 AbbVie 504.43 Bn 477.54 Bn 12.70 Bn 18.33%
4 Merck 367.73 Bn 322.11 Bn 12.21 Bn 26.96%
5 Novartis Ag 303.35 Bn 267.34 Bn 11.24 Bn 38.60%
6 Astrazeneca 268.20 Bn 241.88 Bn 12.86 Bn 6.55%
7 Amgen 242.55 Bn 197.95 Bn 7.24 Bn 34.70%
8 Gilead Sciences 194.80 Bn 169.00 Bn 6.22 Bn 44.00%
9 Pfizer 173.31 Bn 119.95 Bn 10.94 Bn 2.01%
10 Relmada Therapeutics 371.40 Mn -187.18 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -813.97%
Sep 30, 2023 -880.19%
Jun 30, 2023 -973.54%
Mar 31, 2023 -3,051.28%
Dec 31, 2022 -3,318.88%
Sep 30, 2022 -10,100.21%
Jun 30, 2022 -5,251.17%
Mar 31, 2022 -6,169.60%
Dec 31, 2021 -104,716.28%
Dec 31, 2020 -3,089.50%
Sep 30, 2020 -3,441.13%
Dec 31, 2019 49.10%
Sep 30, 2019 -6,683.59%
Mar 31, 2019 -12,622.68%
Sep 30, 2017 -177.67%
Jun 30, 2017 -494,423.79%
Mar 31, 2017 -396,455.60%
Jun 30, 2016 -150,240.14%
Mar 31, 2016 -474,337.28%
Jun 30, 2015 -560,186.28%
API Access

Relmada Therapeutics FCF Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=fcf-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY